[go: up one dir, main page]

FR3078535B1 - Composition vaccinale anti-pd-l1 - Google Patents

Composition vaccinale anti-pd-l1 Download PDF

Info

Publication number
FR3078535B1
FR3078535B1 FR1851895A FR1851895A FR3078535B1 FR 3078535 B1 FR3078535 B1 FR 3078535B1 FR 1851895 A FR1851895 A FR 1851895A FR 1851895 A FR1851895 A FR 1851895A FR 3078535 B1 FR3078535 B1 FR 3078535B1
Authority
FR
France
Prior art keywords
amino acid
sequence
protein
acid residues
chosen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1851895A
Other languages
English (en)
Other versions
FR3078535A1 (fr
Inventor
Lucille Desallais
Jean-Pierre Salles
Jean-Francois Zagury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CNAM Conservatoire National des Arts et Metiers
Peptinov SAS
Original Assignee
CNAM Conservatoire National des Arts et Metiers
Peptinov SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1851895A priority Critical patent/FR3078535B1/fr
Application filed by CNAM Conservatoire National des Arts et Metiers, Peptinov SAS filed Critical CNAM Conservatoire National des Arts et Metiers
Priority to EP19714323.3A priority patent/EP3762402A1/fr
Priority to CN201980029949.5A priority patent/CN112739711A/zh
Priority to JP2020570637A priority patent/JP7560365B2/ja
Priority to PCT/EP2019/055463 priority patent/WO2019170686A1/fr
Priority to US16/978,953 priority patent/US20210395368A1/en
Publication of FR3078535A1 publication Critical patent/FR3078535A1/fr
Application granted granted Critical
Publication of FR3078535B1 publication Critical patent/FR3078535B1/fr
Priority to JP2024023145A priority patent/JP2024077635A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70532B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un polypeptide comprenant, ou constitué de : - une première séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 55 à 67 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une deuxième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 85 à 101 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une troisième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 111 à 127 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une quatrième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 138 à 156 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1 ; et/ou - une cinquième séquence constituée d'au moins 8 résidus d'acides aminés contigus choisis au sein de la séquence s'étendant des résidus d'acides aminés 208 à 223 de la protéine PD-L1 et d'au plus 30 résidus d'acides aminés contigus choisis au sein de la séquence complète de la protéine PD-L1.
FR1851895A 2018-03-05 2018-03-05 Composition vaccinale anti-pd-l1 Active FR3078535B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1851895A FR3078535B1 (fr) 2018-03-05 2018-03-05 Composition vaccinale anti-pd-l1
CN201980029949.5A CN112739711A (zh) 2018-03-05 2019-03-05 抗pd-l1疫苗组合物
JP2020570637A JP7560365B2 (ja) 2018-03-05 2019-03-05 抗pd-l1ワクチン組成物
PCT/EP2019/055463 WO2019170686A1 (fr) 2018-03-05 2019-03-05 Composition vaccinale anti-pd-l1
EP19714323.3A EP3762402A1 (fr) 2018-03-05 2019-03-05 Composition vaccinale anti-pd-l1
US16/978,953 US20210395368A1 (en) 2018-03-05 2019-03-05 Anti-pd-1 vaccine composition
JP2024023145A JP2024077635A (ja) 2018-03-05 2024-02-19 抗pd-l1ワクチン組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1851895 2018-03-05
FR1851895A FR3078535B1 (fr) 2018-03-05 2018-03-05 Composition vaccinale anti-pd-l1

Publications (2)

Publication Number Publication Date
FR3078535A1 FR3078535A1 (fr) 2019-09-06
FR3078535B1 true FR3078535B1 (fr) 2024-02-09

Family

ID=63079997

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1851895A Active FR3078535B1 (fr) 2018-03-05 2018-03-05 Composition vaccinale anti-pd-l1

Country Status (6)

Country Link
US (1) US20210395368A1 (fr)
EP (1) EP3762402A1 (fr)
JP (2) JP7560365B2 (fr)
CN (1) CN112739711A (fr)
FR (1) FR3078535B1 (fr)
WO (1) WO2019170686A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220065784A (ko) * 2019-09-17 2022-05-20 오하이오 스테이트 이노베이션 파운데이션 인간 항-pd-l1 펩티드 백신 및 이의 사용 방법
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6
CN112745384A (zh) * 2021-01-15 2021-05-04 新乡学院 猪pd-l14qn-gf表位多肽及其应用
CN113072620B (zh) * 2021-04-26 2022-07-05 南通大学 一种具有镇痛活性的pd-1靶向肽、其合成方法及其应用
JPWO2024048418A1 (fr) * 2022-08-29 2024-03-07

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
WO2005117983A2 (fr) 2004-06-02 2005-12-15 Cytos Biotechnology Ag Conjugues entraineurs des peptides du tnf
US8703147B2 (en) * 2007-11-05 2014-04-22 The Walter And Eliza Hall Institute Of Medical Research Methods and compositions for treating and preventing malaria (2)
TWI676636B (zh) * 2013-07-12 2019-11-11 Vlp醫療股份有限公司 包含pd-1抗原或pd-1配體抗原的類病毒粒子
CA2936077C (fr) * 2014-01-06 2020-06-30 Expression Pathology, Inc. Dosage srm pour pd-l1
TWI720946B (zh) * 2014-08-08 2021-03-11 美商Vlp醫療股份有限公司 包含改質套膜蛋白質e3之類病毒粒子
KR102610592B1 (ko) * 2015-03-30 2023-12-07 주식회사 에스티큐브 당화 pd-l1에 특이적인 항체 및 그의 사용 방법
US20180201656A1 (en) * 2015-07-04 2018-07-19 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting Pseudomonas Aeruginosa
MX2018011939A (es) * 2016-03-29 2019-05-20 Stcube Inc Anticuerpos de funcion doble especificos para pd-l1 glicosilada y metodos de uso de los mismos.
AU2017254477A1 (en) * 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
RU2743016C2 (ru) * 2016-06-07 2021-02-12 Дойчес Кребсфоршунгсцентрум Улучшение иммуногенности пептида l2 впч
WO2017216384A1 (fr) * 2016-06-17 2017-12-21 Evaxion Biotech Aps Vaccination ciblant ichthyophthirius multifiliis

Also Published As

Publication number Publication date
JP2024077635A (ja) 2024-06-07
FR3078535A1 (fr) 2019-09-06
JP7560365B2 (ja) 2024-10-02
EP3762402A1 (fr) 2021-01-13
CN112739711A (zh) 2021-04-30
US20210395368A1 (en) 2021-12-23
JP2021517472A (ja) 2021-07-26
WO2019170686A1 (fr) 2019-09-12

Similar Documents

Publication Publication Date Title
FR3078535B1 (fr) Composition vaccinale anti-pd-l1
PE20090766A1 (es) Anticuerpo igg1 humanizado
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
TR200202254T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
ATE368853T1 (de) Zell-selektives abgabe system
MA45675B1 (fr) Procédés et compositions pour le traitement du cancer
MA34605B1 (fr) Mutants beta vulgaris tolerents a un herbicide inhibiteurs d'als
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
ATE489462T1 (de) Antimikrobielles polypeptid und nutzung davon
DK0690721T3 (da) Behandling af Mycobakterielle sygdomme ved indgivelse af baktericidt/permeabilitets-forøgende proteinprodukter
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
WO2022169913A3 (fr) Système de dégradation synthétique pour la dégradation ciblée de protéines
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
WO2018094300A8 (fr) Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation
JOP20220110A1 (ar) ناهضات مستقبل npy2
WO2007041285A3 (fr) Complexes de fractions inactivees de pepsines et de proteines de choc thermique
ATE175119T1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
WO2003070176A3 (fr) Defensines modifiees et utilisations de ces dernieres
WO2005059131A3 (fr) Proteine fixant des proteines en miniature et leurs applications
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
DE69529272D1 (de) MONOKLONALER ANTIKÖRPER GEGEN DAS HUMANE Mx-PROTEIN MxA

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190906

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8